Annexon (ANNX) Competitors $6.12 -0.21 (-3.32%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ANNX vs. PLRX, TBPH, ENTA, SNDX, ARVN, JANX, VERA, IOVA, SRRK, and CPRXShould you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Pliant Therapeutics (PLRX), Theravance Biopharma (TBPH), Enanta Pharmaceuticals (ENTA), Syndax Pharmaceuticals (SNDX), Arvinas (ARVN), Janux Therapeutics (JANX), Vera Therapeutics (VERA), Iovance Biotherapeutics (IOVA), Scholar Rock (SRRK), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "medical" sector. Annexon vs. Pliant Therapeutics Theravance Biopharma Enanta Pharmaceuticals Syndax Pharmaceuticals Arvinas Janux Therapeutics Vera Therapeutics Iovance Biotherapeutics Scholar Rock Catalyst Pharmaceuticals Annexon (NASDAQ:ANNX) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations and profitability. Do institutionals & insiders have more ownership in ANNX or PLRX? 97.3% of Pliant Therapeutics shares are owned by institutional investors. 12.7% of Annexon shares are owned by insiders. Comparatively, 6.4% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, ANNX or PLRX? Annexon has higher earnings, but lower revenue than Pliant Therapeutics. Annexon is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnexonN/AN/A-$134.24M-$1.23-4.98Pliant Therapeutics$1.58M478.74-$161.34M-$3.34-3.72 Do analysts prefer ANNX or PLRX? Annexon currently has a consensus target price of $15.80, suggesting a potential upside of 158.17%. Pliant Therapeutics has a consensus target price of $40.57, suggesting a potential upside of 226.40%. Given Pliant Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than Annexon.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annexon 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Pliant Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Is ANNX or PLRX more profitable? Annexon's return on equity of -44.68% beat Pliant Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AnnexonN/A -44.68% -38.02% Pliant Therapeutics N/A -48.91%-41.09% Does the media favor ANNX or PLRX? In the previous week, Annexon had 12 more articles in the media than Pliant Therapeutics. MarketBeat recorded 15 mentions for Annexon and 3 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.90 beat Annexon's score of 0.50 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 1 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pliant Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer ANNX or PLRX? Pliant Therapeutics received 22 more outperform votes than Annexon when rated by MarketBeat users. However, 76.81% of users gave Annexon an outperform vote while only 74.26% of users gave Pliant Therapeutics an outperform vote. CompanyUnderperformOutperformAnnexonOutperform Votes5376.81% Underperform Votes1623.19% Pliant TherapeuticsOutperform Votes7574.26% Underperform Votes2625.74% Which has more volatility & risk, ANNX or PLRX? Annexon has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. SummaryPliant Therapeutics beats Annexon on 9 of the 17 factors compared between the two stocks. Ad WealthPressHow one pattern has averaged an 85% return per year since the pandemic. Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern…Follow this link here and enter your email address to sign up… Get Annexon News Delivered to You Automatically Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANNX vs. The Competition Export to ExcelMetricAnnexonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$646.58M$6.39B$5.06B$8.67BDividend YieldN/A8.04%5.06%4.06%P/E Ratio-4.9810.63100.7117.26Price / SalesN/A266.481,206.6171.28Price / CashN/A53.4940.7536.36Price / Book1.919.306.325.87Net Income-$134.24M$154.14M$119.47M$225.66M7 Day Performance-15.35%-9.49%-5.11%-1.34%1 Month Performance-19.69%-7.23%-3.21%1.00%1 Year Performance139.06%30.70%32.43%25.27% Annexon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANNXAnnexon2.7007 of 5 stars$6.12-3.3%$15.80+158.2%+139.1%$646.58MN/A-4.9860Analyst ForecastShort Interest ↓Analyst RevisionNews CoveragePLRXPliant Therapeutics3.7369 of 5 stars$12.43-3.3%$40.57+226.4%-7.9%$756.42M$1.58M-3.7290TBPHTheravance Biopharma1.9899 of 5 stars$9.52-0.5%$13.75+44.4%-7.5%$465.74M$57.42M-9.43359Earnings ReportNews CoverageENTAEnanta Pharmaceuticals3.9626 of 5 stars$9.53-5.9%$20.00+109.9%+9.7%$201.94M$79.20M-1.75145Upcoming EarningsSNDXSyndax Pharmaceuticals3.4656 of 5 stars$15.83-5.7%$36.00+127.4%+6.9%$1.35B$139.71M-4.36110Analyst ForecastNews CoverageHigh Trading VolumeARVNArvinas2.3286 of 5 stars$22.48-9.8%$60.00+166.9%+8.1%$1.54B$78.50M-4.81445Short Interest ↓JANXJanux Therapeutics3.593 of 5 stars$48.76-4.6%$66.44+36.3%+452.8%$2.56B$8.08M-41.6730Analyst ForecastVERAVera Therapeutics3.4665 of 5 stars$46.26-5.6%$57.88+25.1%+249.9%$2.54BN/A-17.7240IOVAIovance Biotherapeutics4.278 of 5 stars$8.18-4.8%$22.33+173.0%+85.9%$2.49B$1.19M-5.49500Insider SellingHigh Trading VolumeSRRKScholar Rock4.6067 of 5 stars$26.49-3.7%$34.00+28.4%+125.3%$2.48B$33.19M-11.27140Analyst ForecastAnalyst RevisionNews CoverageCPRXCatalyst Pharmaceuticals4.7199 of 5 stars$20.60-5.0%$30.50+48.1%+54.0%$2.46B$398.20M17.46167 Related Companies and Tools Related Companies PLRX Competitors TBPH Competitors ENTA Competitors SNDX Competitors ARVN Competitors JANX Competitors VERA Competitors IOVA Competitors SRRK Competitors CPRX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANNX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
